New blood test could replace risky prenatal procedures

NCT ID NCT07469657

Recruiting now Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study tests a new blood test that looks for severe genetic diseases in unborn babies using a sample from the mother. The test analyzes fetal DNA found in the mother's blood, which could avoid the need for invasive procedures like amniocentesis that carry a small risk of miscarriage. Researchers will compare the costs and benefits of this approach with current methods in 300 couples at risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: blood test using next-generation sequencing of fetal DNA
What this could lead to: If successful, this could offer a safer, earlier alternative to invasive prenatal testing for many genetic conditions, reducing the risk of miscarriage.
What could go wrong: This is a health economics study, not a treatment trial. It will assess costs and feasibility, not prove the test works for all conditions. The test may not be widely available or affordable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENETIC DISEASES, INBORN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENETIC DISEASES, INBORN MONOGENIC DISEASES

Contacts and locations

Locations

Hôpital Necker Enfants Malades
RECRUITING

Paris, Île-de-France Region, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.